Santos da Silva Jorge insider trades
Santos da Silva Jorge has filed 11 Form 4s with the SEC that we hold, all for MoonLake Immunotherapeutics (MLTX), as Chief Executive Officer, Director. Across all of them we count 0 purchases worth $0 and 14 sales worth $19.2M reported on Form 4. In the last 12 months: 0 purchases ($0) and 7 sales ($8.7M). The largest single trade was a sale of 62,810 shares of MoonLake Immunotherapeutics worth $3.5M, dated 2024-02-27. The first filing on our record is dated 2023-10-03 and the latest 2026-07-13.
MoonLake Immunotherapeutics (MLTX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-02-15 | S, sale reported on Form 4 | 20,000 | $1.2M | 2024-02-20 |
| 2024-02-16 | S, sale reported on Form 4 | 20,000 | $1.2M | 2024-02-20 |
| 2024-02-20 | S, sale reported on Form 4 | 20,000 | $1.1M | 2024-02-20 |
| 2024-02-21 | S, sale reported on Form 4 | 1,125 | $62.2K | 2024-02-23 |
| 2024-02-27 | S, sale reported on Form 4 | 62,810 | $3.5M | 2024-02-29 |
| 2024-02-28 | S, sale reported on Form 4 | 56,065 | $3.1M | 2024-02-29 |
| 2024-02-29 | S, sale reported on Form 4 | 4,740 | $264.9K | 2024-02-29 |
| 2025-12-08 | S, sale reported on Form 4 | 130,000 | $2.0M | 2025-12-10 |
| 2025-12-09 | S, sale reported on Form 4 | 70,000 | $1.0M | 2025-12-10 |
| 2026-04-10 | S, sale reported on Form 4 | 98,127 | $1.8M | 2026-04-14 |
| 2026-04-13 | S, sale reported on Form 4 | 51,873 | $945.6K | 2026-04-14 |
| 2026-07-01 | S, sale reported on Form 4 | 47,775 | $956.9K | 2026-07-02 |
| 2026-07-09 | S, sale reported on Form 4 | 33,936 | $679.1K | 2026-07-13 |
| 2026-07-10 | S, sale reported on Form 4 | 68,289 | $1.4M | 2026-07-13 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1920509) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms